We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

New England Peptide Unveils Peptide Array Flash Purification System

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
New England Peptide (NEP) has introduced the peptide industry’s first flash purification system, which can prepare research grade peptides for its customer use worldwide.

NEP’s proprietary process, named FlashPure™, transforms unpurified arrays, or “crude” peptide libraries, into partially purified peptides that have improved solubility and are free of excess salts and other impurities that are common in other similar products on the market.

“NEP’S FlashPure™ process provides researchers with improved reproducibility and confidence in their results,” stated Dr. Robert Hammer, NEP’s Vice President for Chemical Development. “Contaminants including excess acids and organic reagents as well as other side products are common in most crude peptide libraries but are incompatible with many cellular assays. Compared with crude array products, assays run with NEP’s FlashPure™ will have less unpredictable effects due to hydrophobic contaminants and salts.”

These contaminants can result in false negatives or false positives in many kinds of assays and can contribute to poor solubility of the peptides for applications in biological screening. Removing these potential roadblocks leads to more reliable data and interpretation of results.

FlashPure™ is one of many new products and services emanating from the NEP’s in-house development team, headed by Dr. Hammer.

FlashPure™ is designed to create peptide arrays that behave more like purified peptides at a fraction of the time and cost required to purify a peptide through the traditional processes. This service will address the needs of a variety of disciplines including bioassays, proteomics, biomarker discovery, drug screening, target validation, epitope mapping, and structure-activity studies.